Broad Band Light for the Treatment and Prevention of Senile Purpura

Senile Purpura Clinical Trial

Official title:

A Prospective, Randomized, Split-Arm Pilot Study Investigating the Efficacy and Safety of Sciton's Broad Band Light for Improving the Clinical Signs of Senile Purpura

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03690375
• Other study ID #: Purpura001
• Status: Completed
• Phase: N/A
• Start date: August 27, 2018
• Est. completion date: November 11, 2019

Study information

• Verified date: November 2019
• Source: Siperstein Dermatology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There will be five subjects over the age of 65, each with at least one ecchymotic lesion on each arm measuring at least one cm, and five control subjects under the age of 35, both who will be randomized to undergo 4 Sciton Broad Band Light (BBL) treatments on either their left or right arm one week apart. Subjects will fill out questionnaires, have pictures of their lower arms taken, and will be graded and measured by evaluators regarding the number and size of their ecchymoses as well as side effects such as blistering, pain, erythema, and swelling. One day after their 4th treatment on each arm, subjects will have biopsies done to be analyzed for changes in histology and gene expression. The subjects will follow up 1 month after their last treatments for final pictures of their lower arms and evaluations.

Description:

This will be a single center, prospective, split-arm clinical study in which subjects will be randomized to which arm will be treated with Sciton's broad band light (BBL) treatment. All subjects will have their arms shaved prior to the procedure and cleaned thoroughly with alcohol. After the procedure a zinc-based sunscreen will be applied to both arms. Before each of the four treatments, and 1 month after the last treatment, the subjects' number and square area of ecchymoses will be measured by an evaluator and photographs will be taken. Side effects will be measured the same day as the treatment as well as 1 day, 2 days, and 7 days after the first treatment. A final assessment will be done by taking two skin biopsies from the subjects with senile purpura, one on treated skin and one on untreated skin, and one skin biopsy on untreated skin in the younger controls. The skin specimens will be bisected and one half will be submerged immediately in 10x volumes of formalin while the other half of the biopsy will be submerged immediately in 10x volumes of RNAlater (Thermo Fisher Scientific, Waltham, MA). These specimens will then be coded and sent to blinded evaluators that will embed half in paraffin sections and then stain them with hematoxylin and eosin (H&E), von Giesen and or periodic acid-Schiff (PAS). Epidermal thickness will be measured on H&E-stained sections using the AxioVision image analysis software (Carl Zeiss Microimaging, Thornwood, NY). The epithelial thickness may vary from area to area within the biopsy. The thickness of the epithelium in µm will be measured at 6 points in each biopsy and averaged. Von Giesen-stained sections will be examined for elastosis, and PAS-stained sections will be examined for collagen. Total RNA will be extracted using TRIzol Reagent (Thermo Fisher Scientific, Waltham, MA) and the RNeasy mini kit (Qiagen, Valencia, CA). RNA will be reverse transcribed using qScript™ cDNA Synthesis Kit (QuantaBio, Beverly, MA). Real-time qPCR reactions will be carried out using PerfeCTa SYBR® Green SuperMix (QuantaBio, Beverly, MA) in triplicates. Gene expression levels will be normalized to a housekeeping gene, and analyzed using t test of means and SEM. Potential analysis include various biomarkers for dermal remodeling (e.g., collagen type I, elastin), epidermal differentiation (e.g., keratin 1, filaggrin), and vascular changes (e.g., endothelin, Ang).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: November 11, 2019
• Est. primary completion date: October 15, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Male or female, aged >22
• In good general health as evidenced by medical history
• Ecchymosis greater than 1cm on each arm for the group with senile purpura Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation

in this study:

• Subjects with a history of any arm swelling
• Subjects with allergies to light
• Subjects with auto-immune skin conditions such as lupus, or vitiligo
• Subjects using topical retinol within the last 3 months
• Subjects with any scheduled laser, light, or surgical procedures on the arm during the study
• Subjects unwilling or unable to keep their arms still during digital pictures
• Subjects who are pregnant or nursing
• Subjects with a history of herpes simplex or zoster on their arms
• Subjects with current skin infections, tumors, or dermatitis on the arm
• Subjects with allergies to lidocaine
• Subjects with a history of keloid formation
• Subjects with a history of a bleeding disorder
• Subjects with allergies to adhesives

Related Conditions & MeSH terms

• Bateman's Purpura
• Purpura
• Senile Purpura

Intervention

Device:
• Broad Band Light (BBL)
Sciton's BBL treatment using a new protocol that utilizes a 590nm, 560nm, and skintyte filter

Locations

Country	Name	City	State
United States	Siperstein Dermatology Group	Boynton Beach	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Siperstein Dermatology	University of Miami

Country where clinical trial is conducted

United States, 

References & Publications (7)

Bitter PH. Noninvasive rejuvenation of photodamaged skin using serial, full-face intense pulsed light treatments. Dermatol Surg. 2000 Sep;26(9):835-42; discussion 843. — View Citation

Brauer JA, Farhadian JA, Bernstein LJ, Bae YS, Geronemus RG. Pulsed Dye Laser at Subpurpuric Settings for the Treatment of Pulsed Dye Laser-Induced Ecchymoses in Patients With Port-Wine Stains. Dermatol Surg. 2018 Feb;44(2):220-226. doi: 10.1097/DSS.0000000000001255. — View Citation

Chang AL, Bitter PH Jr, Qu K, Lin M, Rapicavoli NA, Chang HY. Rejuvenation of gene expression pattern of aged human skin by broadband light treatment: a pilot study. J Invest Dermatol. 2013 Feb;133(2):394-402. doi: 10.1038/jid.2012.287. Epub 2012 Aug 30. Erratum in: J Invest Dermatol. 2013 Jun;133(6):1691. — View Citation

DeFatta RJ, Krishna S, Williams EF 3rd. Pulsed-dye laser for treating ecchymoses after facial cosmetic procedures. Arch Facial Plast Surg. 2009 Mar-Apr;11(2):99-103. doi: 10.1001/archfacial.2008.538. — View Citation

Faucz LL, Will SE, Rodrigues CJ, Hesse H, Moraes AC, Maria DA. Quantitative evaluation of collagen and elastic fibers after intense pulsed light treatment of mouse skin. Lasers Surg Med. 2018 Jan 16. doi: 10.1002/lsm.22782. [Epub ahead of print] — View Citation

McKenzie NE, Saboda K, Duckett LD, Goldman R, Hu C, Curiel-Lewandrowski CN. Development of a photographic scale for consistency and guidance in dermatologic assessment of forearm sun damage. Arch Dermatol. 2011 Jan;147(1):31-6. doi: 10.1001/archdermatol.2010.392. — View Citation

Prieto VG, Sadick NS, Lloreta J, Nicholson J, Shea CR. Effects of intense pulsed light on sun-damaged human skin, routine, and ultrastructural analysis. Lasers Surg Med. 2002;30(2):82-5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions	The number of purpuric lesions 30 days after the last treatment will be subtracted from the number of purpuric lesions at baseline	51 days (Treatments done every 7 days starting on Day 0 and ending on Day 21, then the final outcome was measured 30 days after the last treatment)
Primary	The Change in Total Square Size of Purpuric Lesions From Baseline to 30 Days After the Last Treatment	The size of the purpuric lesions will be measured by multiplying the height by the width in cm of each lesion and totaling the total cm2 area for each lesion on each arm. Then the total square area 30 days after the last treatment will be subtracted from the total square area at baseline.	51 Days (30 days after the final treatment at Day 21)
Secondary	Epidermal Thickness 1 Day After the Fourth BBL Treatment	Measurement of epidermal thickness in um as measured by H&E stained sections using the AxionVision image analysis software based on slides from biopsies taken from the subjects 1 days after their last treatment.	22 days (1 day after final treatment at day 21)